Leflunomide in Systemic Lupus Erythematosus

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A pilot study to evaluate the efficacy and safety of leflunomide in SLE patients with active disease who are refractory to cyclophosphamide

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Leflunomide

Criteria

Inclusion Criteria:

• Fulfill the revised ACR criteria for SLE with either evidence of active disease according to SLE Disease Activity Index (SLEDAI)

Exclusion Criteria:

• Patients who are pregnant or nursing women, or those with life threatening disease

• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.